ArticleClinical cardiology2026
Enhancing Heart Failure Detection in the General Population Using the Steatosis-Associated Fibrosis Estimator.
Article in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNon-alcoholic fatty liver disease and its fibrotic sequelae have been implicated in the development of cardiovascular complications. This study investigated the association between the steatosis-associated fibrosis estimator (SAFE) and prevalent heart failure (HF), as well as evaluated whether SAFE could improve HF detection in the general population.
methodsA total of 33,566 participants from the 2003-2018 National Health and Nutrition Examination Survey were included. HF was identified based on self-reported medical history.
resultsThe estimated HF prevalence was 3.00%. After adjusting for demographic, anthropometric, laboratory, and medical history factors, each one-standard-deviation increase in SAFE correlated with a 58.0% rise in HF risk. Individuals in the highest quartile of SAFE had a 2.777-fold risk of HF compared to those in the lowest quartile. Smooth-curve modeling revealed an almost linear association between SAFE and HF, and subgroup analyses supported this relationship across diverse populations. Incorporating SAFE into standard cardiovascular risk factors slightly improved HF discrimination (AUC: 0.873 vs. 0.876, p < 0.001). Reclassification metrics provided additional evidence for SAFE's incremental value.
conclusionThis study identified a nearly linear and robust relationship between SAFE and prevalent HF, suggesting that SAFE may serve as a useful indicator for enhancing HF detection in the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.